Theriva's High-Stakes Cancer Bet Amid Financial Warning

ROCKVILLE, MD – March 12, 2026 – Theriva Biologics, a clinical-stage company focused on hard-to-treat cancers, today announced significant progress in its oncology pipeline, signaling a potential new front in the war against pancreatic cancer and a rare pediatric eye cancer. However, the promising clinical news, detailed in its full-year 2025 financial report, is shadowed by a stark auditor's warning about the company's ability to continue as a "going concern," placing Theriva on a precarious tightrope between breakthrough and bankruptcy.

The company is advancing its lead candidate, VCN-01, toward pivotal late-stage trials after receiving encouraging feedback from European regulators. It also strategically licensed out a non-core asset to bolster its cash reserves. Yet, with a cash runway extending only into early 2027, the firm faces an urgent race against time to fund the very trials that could validate its innovative science and bring life-altering therapies to patients in desperate need.

A Laser Focus on Oncology

At the heart of Theriva's strategy is VCN-01, an oncolytic adenovirus engineered to be a multi-pronged weapon against tumors. Administered intravenously, it is designed to hunt down and selectively replicate within cancer cells, causing them to burst. Critically, it also degrades the dense, fibrous matrix, or stroma, that encases many tumors, a barrier that often shields them from chemotherapy and the body's own immune system. This dual action aims to kill cancer cells directly while also opening the door for co-administered treatments to be more effective.

Pancreatic ductal adenocarcinoma (PDAC), a disease with a notoriously grim prognosis, is the company's primary target. Theriva recently received positive scientific advice from the European Medicines Agency (EMA) for a proposed Phase 3 trial of VCN-01 combined with standard-of-care chemotherapy for metastatic PDAC. The EMA expressed general agreement with the trial's design, including its size, dosing regimen, and primary endpoint of overall survival—a significant regulatory milestone that provides a clearer path forward in Europe.

“We continue to advance our lead oncolytic virus candidate VCN-01 towards pivotal clinical development in multiple indications of high unmet need,” said Steven A. Shallcross, Chief Executive Officer of Theriva Biologics, in the company's press release. “With the recent feedback from the EMA, we have further clarity on dosing regimen, protocol and overall design for our proposed Phase 3 trial in pancreatic ductal adenocarcinoma (PDAC).”

Building on this momentum, Theriva plans an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in the first half of 2026 to finalize plans for a multinational pivotal trial. The candidate has already secured Fast Track and Orphan Drug designations from the FDA for pancreatic cancer, highlighting the significant unmet need.

Beyond pancreatic cancer, VCN-01 is also being developed for retinoblastoma, the most common eye cancer in children. For this indication, the drug has received both Orphan Drug and Rare Pediatric Disease designations from the FDA. The latter could yield a valuable Priority Review Voucher if the drug is approved, a tradable asset that can be sold to other companies for tens of millions of dollars, providing a potential source of non-dilutive funding.

The Price of Progress

While the clinical pathway for VCN-01 is becoming clearer, the financial path is fraught with uncertainty. Included in the company's annual report is an explanatory paragraph from its independent auditor regarding its ability to continue as a "going concern." This formal warning signifies substantial doubt about the company's capacity to meet its financial obligations over the next twelve months without securing significant additional capital.

Such warnings are not uncommon in the cash-intensive biotech sector, where companies burn through millions in research and development long before any revenue is generated. However, it remains a serious red flag for investors and a stark reminder of the financial pressures at play. As of February 26, 2026, Theriva reported having $15.2 million in cash and cash equivalents, which it projects will fund operations only into the first quarter of 2027. This runway is critically short for a company on the cusp of launching costly, large-scale Phase 3 trials.

The company's 2025 financial statements reflect this high-stakes environment. Research and development expenses decreased 28% to $8.6 million, largely due to the completion of a Phase 2b trial for VCN-01. In contrast, general and administrative expenses more than doubled to $15.4 million. This surge was primarily driven by a one-time, non-cash charge of $9.0 million for contingent consideration, a payment triggered by VCN-01 achieving its primary endpoints in the VIRAGE Phase 2b trial—a cost incurred precisely because the drug showed success.

Strategic Maneuvers to Stay in the Fight

Facing these financial headwinds, Theriva's management is making calculated moves to extend its runway and sharpen its focus. A key development was the recent out-licensing of SYN-020, a non-oncology asset, to the privately-held Rasayana Therapeutics.

SYN-020 is a recombinant protein designed to address inflammatory gut conditions. By handing off its development to Rasayana, Theriva sheds future R&D costs associated with the program. In return, Theriva received a modest $300,000 upfront payment but is eligible for up to $38 million in future development, regulatory, and sales milestones, plus royalties. While these back-end payments are speculative and contingent on Rasayana's success, the deal immediately streamlines Theriva's operations and reinforces its commitment to the oncology pipeline.

“We are very pleased to have completed the licensing of our versatile Phase 2-ready asset SYN-020 to Rasayana Therapeutics, executing on our plan to derive value from our GI portfolio while we remain focused on the advancement of our oncology pipeline,” Shallcross stated.

This licensing deal, combined with several capital raises in 2025, represents a multi-pronged effort to keep the company funded. However, management acknowledges this is not enough. The company's own statements confirm it is actively pursuing partnerships to help fund the extensive costs of VCN-01 manufacturing scale-up and the upcoming pivotal trials. Securing a deep-pocketed partner will be crucial to navigating the financial valley that lies between its current position and potential commercialization.